Supernus Pharmaceuticals Inc. Watch

EX-10.1

from 10-Q 52 pages Settlement Agreement by and Between Supernus Pharmaceuticals, Inc. and Ascent Pharmaceuticals, Inc. Dated as of April 30, 2024

12/34/56

EX-10.48

from 10-K 33 pages Settlement Agreement by and Between Supernus Pharmaceuticals, Inc. and Apotex Inc. Apotex Corp. Dated as of June 21, 2023

12/34/56

EX-10.44

from 10-K 7 pages Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan Performance Share Unit Award Agreement

12/34/56

EX-10.42

from 10-K 5 pages Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan Restricted Stock Unit Agreement Supernus Pharmaceuticals, Inc. Strongly Encourages You to Seek the Advice of Your Own Legal and Financial Advisors With Respect to Your Award and Its Tax Consequences

12/34/56

EX-10.40

from 10-K 4 pages Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan Supernus Pharmaceuticals, Inc. Strongly Encourages You to Seek the Advice of Your Own Legal and Financial Advisors With Respect to Your Award and Its Tax Consequences. Form of Non-Statutory Time-Based Stock Option Agreement

12/34/56

EX-10.38

from 10-K 4 pages Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan Supernus Pharmaceuticals, Inc. Strongly Encourages You to Seek the Advice of Your Own Legal and Financial Advisors With Respect to Your Award and Its Tax Consequences. Form of Time-Based Incentive Stock Option Agreement

12/34/56

EX-10.16

from 10-K 9 pages Form of Executive Retention Agreement

12/34/56

EX-10.71

from 10-K 34 pages Settlement Agreement by and Between Supernus Pharmaceuticals, Inc. and Zydus Pharmaceutical (USA) Inc. Zydus Lifesciences Limited Dated as of December 31, 2022

12/34/56

EX-10.1

from 8-K 21 pages Certain Confidential Information Identified in This Document, Marked by [*], Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed

12/34/56

EX-10.1

from 10-Q 5 pages Amendment to Deed of Lease

12/34/56

EX-10.6

from 10-Q 7 pages Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan Performance Share Unit Award Agreement

12/34/56

EX-10.5

from 10-Q 4 pages Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan Restricted Stock Unit Award Agreement

12/34/56

EX-10.4

from 10-Q 4 pages Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan Supernus Pharmaceuticals, Inc. Strongly Encourages You to Seek the Advice of Your Own Legal and Financial Advisors With Respect to Your Award and Its Tax Consequences. Form of Non-Statutory Time-Based Stock Option Agreement

12/34/56

EX-10.3

from 10-Q 4 pages Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan Supernus Pharmaceuticals, Inc. Strongly Encourages You to Seek the Advice of Your Own Legal and Financial Advisors With Respect to Your Award and Its Tax Consequences. Form of Time-Based Incentive Stock Option Agreement

12/34/56

EX-10.2

from 10-Q 34 pages Certain Confidential Information Identified in This Document, Marked by [**], Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed Api Supply Agreement

12/34/56

EX-10.1

from 10-Q 44 pages Certain Confidential Information Identified in This Document, Marked by [**], Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed

12/34/56

EX-10.1

from 8-K 2 pages Certain Confidential Information Identified in This Document, Marked by [**], Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed

12/34/56

EX-10.12

from 10-K 19 pages Certain Confidential Information Identified in This Document, Marked by [**], Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Purchase and Sale Agreement

12/34/56

EX-10.11

from 10-K 38 pages Certain Confidential Information Identified in This Document, Marked by [**], Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. June 6, 2006 Exclusive License Agreement Between Supernus Pharmaceuticals Inc. and United Therapeutics Corporation

12/34/56

EX-10.10

from 10-K 21 pages Certain Confidential Information Identified in This Document, Marked by [**], Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Guanfacine License Agreement

12/34/56